Propylene Glycol Ethers: Widespread Use and Missing Neurotoxicity Testing

Organic solvents are known to affect the nervous system, but neurotoxicity testing is not routinely required for industrial chemicals under current European regulations. Glycol ethers are widely used in consumer and industrial products. They can cross skin and lung barriers, distribute systemically, and penetrate the blood-brain barrier due to their physicochemical properties, while their neurotoxic potential remains poorly characterized. P-series glycol ethers now dominate the European market, making exposure assessment critical for public health. We compiled and integrated data from five authoritative sources to build an inventory of glycol ethers currently used in Europe and performed a structured descriptive analysis of high-volume propylene glycol ether compounds. Six high-volume compounds (≥1000 t/year) were selected for analysis. Production volumes, Swiss product registrations, occupational exposure limits, and product categories were compiled. Propylene glycol methyl ether (PGME) showed the highest tonnage (100,000-1,000,000 t/year) and was present in 9497 registered products, followed by propylene glycol ethyl ether (PGEE) (10,000-100,000 t/year; 1333 products). Paints/coatings and cleaning agents were the most frequent product categories, while additional presence in personal care and indoor-use products was observed. These products may lead to exposure depending on use conditions, such as spraying or inadequate ventilation, which can increase inhalation and skin contact. Their presence in diverse products suggests potential for both occupational and chronic low-level exposures. By providing an integrated overview of market presence, use patterns, and available neurotoxicity evidence for propylene glycol ethers, our findings highlight a critical gap in chemical risk assessment: the absence of neurotoxicity testing despite high production volumes and widespread use. Integrating neurotoxicity endpoints and new approach methodologies into regulatory frameworks is essential to strengthen public health protection.

Authors

Institutions

Publication Details

Journal
Toxics
Published
2026-03-09
DOI
https://doi.org/10.3390/toxics14030232
Primary Topic
Carcinogens and Genotoxicity Assessment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Propylene Glycol Ethers: Widespread Use and Missing Neurotoxicity Testing

Nancy B. Hopf, Hélène P. De Luca
Toxics
Carcinogens and Genotoxicity Assessment
article

Propylene Glycol Ethers: Widespread Use and Missing Neurotoxicity Testing

Nancy B. Hopf, Hélène P. De Luca
article en

Abstract

Organic solvents are known to affect the nervous system, but neurotoxicity testing is not routinely required for industrial chemicals under current European regulations. Glycol ethers are widely used in consumer and industrial products. They can cross skin and lung barriers, distribute systemically, and penetrate the blood-brain barrier due to their physicochemical properties, while their neurotoxic potential remains poorly characterized. P-series glycol ethers now dominate the European market, making exposure assessment critical for public health. We compiled and integrated data from five authoritative sources to build an inventory of glycol ethers currently used in Europe and performed a structured descriptive analysis of high-volume propylene glycol ether compounds. Six high-volume compounds (≥1000 t/year) were selected for analysis. Production volumes, Swiss product registrations, occupational exposure limits, and product categories were compiled. Propylene glycol methyl ether (PGME) showed the highest tonnage (100,000-1,000,000 t/year) and was present in 9497 registered products, followed by propylene glycol ethyl ether (PGEE) (10,000-100,000 t/year; 1333 products). Paints/coatings and cleaning agents were the most frequent product categories, while additional presence in personal care and indoor-use products was observed. These products may lead to exposure depending on use conditions, such as spraying or inadequate ventilation, which can increase inhalation and skin contact. Their presence in diverse products suggests potential for both occupational and chronic low-level exposures. By providing an integrated overview of market presence, use patterns, and available neurotoxicity evidence for propylene glycol ethers, our findings highlight a critical gap in chemical risk assessment: the absence of neurotoxicity testing despite high production volumes and widespread use. Integrating neurotoxicity endpoints and new approach methodologies into regulatory frameworks is essential to strengthen public health protection.

ToxicsVol. 14(3)
Centre universitaire de médecine générale et santé publique, Lausanne (CH)
Swiss Centre for Applied Human Toxicology
Openalex Percentile: Top 28%
Carcinogens and Genotoxicity Assessment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Propylene Glycol Ethers: Widespread Use and Missing Neurotoxicity Testing — Nancy B. Hopf, Hélène P. De Luca · Toxics (2026) | TGRS Research Map | TGRS